Core Viewpoint - The article discusses the high salaries of chairpersons in the A-share medical industry, highlighting discrepancies between their compensation and company performance, particularly in firms that have not turned a profit [2][3][9]. Group 1: Salary Comparisons - Among 4,231 listed companies, only 13 chairpersons earn over 10 million yuan annually, with the top three from the medical sector: WuXi AppTec (41.8 million yuan), Mindray (24.94 million yuan), and BeiGene (20.19 million yuan) [2][4]. - The average salary for chairpersons in the medical sector is 174,000 yuan, higher than the overall average of 137,000 yuan for all listed companies [4][8]. - In 2024, the average salaries for chairpersons in various medical sub-sectors showed a decline, with the pharmaceutical sector down 4.75% to 167,000 yuan, and medical services down 7.13% to 227,000 yuan [4][6]. Group 2: Discrepancies in Salary and Performance - Companies like BeiGene, which has never been profitable since its IPO, still pay their chairperson a salary of 20.19 million yuan despite significant losses, including a net loss of 4.978 billion yuan last year [9][11]. - Other companies, such as Rongchang Biologics and Junshi Biosciences, also exhibit high chairperson salaries despite continuous losses, raising questions about the justification for such compensation [11][9]. - The article notes that the correlation between chairperson salaries and company performance metrics like revenue and net profit is weak, with a correlation coefficient of only 0.52 with net profit [8]. Group 3: Ethical Considerations - The article raises concerns about the ethical implications of high salaries for chairpersons in companies facing legal issues or financial difficulties, such as WeiNing Health and Lao Bai Xing Pharmacy, where chairpersons continue to receive substantial compensation despite scandals [13][14]. - The medical industry, being sensitive to public health and welfare, necessitates responsible governance, and the continued high compensation for chairpersons amidst company troubles is viewed as unreasonable [15].

Investment Rating - The report suggests a positive outlook on the pharmaceutical industry, particularly focusing on innovative drugs and potential treatments for cancer cachexia [1][11]. Core Insights - The report highlights the complexity of cancer cachexia and the limited treatment options currently available, emphasizing the importance of developing targeted therapies [17][18]. - It identifies key companies to watch, including Changchun High-tech, Kexing Pharmaceutical, Sunshine Nuohuo, Shiyao Group, and Jinfang Pharmaceutical, which are involved in promising drug candidates [1][17]. - The report anticipates a structural bull market in the pharmaceutical sector, driven by innovative drugs and new technologies [3][14]. Summary by Sections 1. Industry Performance - The pharmaceutical index increased by 1.27% during the week of May 12-16, underperforming the ChiNext index but outperforming the CSI 300 index [1][12]. 2. Cancer Cachexia Insights - Cancer cachexia affects 60%-80% of cancer patients, with approximately 20% of these patients dying from it, highlighting the critical need for effective treatments [17]. - The report discusses the mechanisms of cancer cachexia, including metabolic abnormalities and inflammatory responses, which complicate treatment options [18][21]. 3. Potential Drug Targets - The report identifies GDF15/GFRAL and GHSR as key potential drug targets for cancer cachexia, with several companies developing therapies targeting these pathways [27][35]. - Notable drug candidates include ponsegromab by Pfizer, which has shown promising results in clinical trials [33]. 4. Investment Strategies - The report outlines investment strategies focusing on innovative drugs, including overseas big pharma, early-stage research, and undervalued generics [15][16]. - It emphasizes the importance of self-sufficiency and restructuring the supply chain within the pharmaceutical industry [5][14]. 5. Future Outlook - The report predicts a favorable trading atmosphere for the pharmaceutical sector in 2025, with a high likelihood of structural growth driven by innovative drugs and new technologies [3][14].

Core Viewpoint - The A-share market has seen a significant increase in institutional research activity since May, with over 2,000 listed companies being investigated, particularly in high-end manufacturing, semiconductors, and healthcare sectors [1][2]. Group 1: Institutional Research Trends - Public fund research has accelerated, with notable interest in high-end manufacturing, semiconductors, and healthcare, highlighting a strong focus on technological breakthroughs and policy benefits [2][3]. - The top three public funds conducting research are Bosera Fund with 51 instances, followed by Fortune Fund and Penghua Fund with 49 and 46 instances respectively, indicating a trend of high-frequency research to identify quality targets [3]. - The research frequency in high-end manufacturing, semiconductor equipment, and innovative pharmaceuticals accounts for over 60% of total investigations, reflecting a structural preference among institutional investors [3][4]. Group 2: Sector Focus - The computer, communication, and other electronic equipment manufacturing sectors lead with over 34 companies being researched, focusing on semiconductor materials, consumer electronics, and industrial automation [4]. - The healthcare manufacturing sector follows with 23 companies under investigation, with firms like BeiGene and Sunlight Nuohe gaining attention due to innovative drug development and recovery in medical consumption [4]. - Specific companies such as BeiGene-U, Anji Technology, and Hengerd have received the highest attention from institutions, with 256, 241, and 234 institutions respectively conducting research on them [4]. Group 3: Overseas Market and Tariff Impact - Fund managers are particularly focused on companies' overseas market strategies and the impact of US-China tariffs, with firms like Shenzhen South Circuit revealing significant investments in Thailand to enhance global supply chain capabilities [5]. - The expectation of a recovery in market sentiment regarding US-China trade tensions is influencing investment strategies, with a focus on self-sufficiency and domestic demand-driven opportunities [5][6]. Group 4: Investment Outlook - The current market environment is seen as a critical transition period for asset allocation, with expectations of gradual strengthening in the stock market despite potential volatility [7]. - There is a growing interest in "safe" assets such as military, gold, and rare earths, alongside technology sectors represented by AI and high-end manufacturing, as key investment themes moving forward [7].

Group 1 - The core index, the CESHKB, increased by 1.98% to 5775.66 points, with a trading volume of 6.408 billion [1] - Over the past month, the CESHKB has risen by 7.34%, by 17.05% over the last three months, and by 28.90% year-to-date [1] - The CESHKB is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, set at 2000.0 points [1] Group 2 - The top ten holdings of the CESHKB include: Innovent Biologics (10.8%), CanSino Biologics (10.42%), WuXi Biologics (10.27%), China National Pharmaceutical Group (9.64%), BeiGene (9.22%), Kelun-Biotech (5.32%), Zai Lab (5.26%), WuXi AppTec (5.16%), 3SBio (5.15%), and Genscript Biotech (3.23%) [1] - The CESHKB is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% representation [2] - The industry representation of the CESHKB is entirely in the healthcare sector, specifically pharmaceuticals and biotechnology, also at 100% [2]

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology industry, suggesting it is at a turning point for profit improvement and has high allocation value [3][4]. Core Insights - The pharmaceutical sector is showing signs of recovery after three years of declining profitability, with a notable increase in net profit margin by 0.3% in Q1 2025 compared to the previous year [3][5]. - Key sub-sectors such as CXO, innovative drugs, biological products, private hospitals, and medical consumables have demonstrated strong performance in Q1 2025, with several leading companies exceeding expectations [3][4]. - The report recommends focusing on sub-sectors and companies with clear upward trends in performance, including innovative drugs and CXO services [3][4]. Overall Performance of the Sector - In 2024, 473 A-share pharmaceutical companies achieved total revenue of 24,588 billion yuan, a year-on-year decrease of 0.9%, and a net profit of 1,412 billion yuan, down 12.1% [3][5]. - For Q1 2025, the sector reported revenue of 6,104 billion yuan, a decline of 4.2% year-on-year, with net profit at 487 billion yuan, down 8.7% [3][5]. Sub-sector Performance - The CXO sector has shown a turnaround since Q4 2024, with Q1 2025 revenue of 225 billion yuan, reflecting an 11.6% year-on-year increase, and net profit of 50 billion yuan, up 72.8% [3][23]. - The innovative drug sector continues to grow rapidly, with leading companies like Heng Rui Medicine and Bai Jie Shen Zhou performing above expectations [3][18]. - The hospital sector is beginning to show signs of recovery, with Q1 2025 revenue of 144 billion yuan, a year-on-year increase of 4.9%, and net profit of 11 billion yuan, up 19.2% [3][28]. Investment Analysis - The report emphasizes the importance of investing in sectors and companies that are showing clear signs of upward trends, particularly in innovative drugs and CXO services [3][4]. - Specific companies recommended for investment include Heng Rui Medicine, Bai Jie Shen Zhou, and Wu Xi AppTec in the innovative drug and CXO sectors [3][4].

Group 1 - Meituan leads a Series A funding round for Zivariable Robotics, which has raised over 1 billion yuan since its establishment [1] - Zivariable Robotics focuses on "end-to-end large model" technology, integrating multimodal information for a complete feedback loop from perception to execution [1] - Meituan aims to build a comprehensive technology system in the robotics field by investing in various companies with different technological paths [1] Group 2 - HHLR Advisors reported a significant increase in total market value of holdings from $2.89 billion to $3.54 billion, a nearly 23% rise [2] - The top ten holdings of HHLR Advisors are dominated by Chinese companies, with nine out of ten being Chinese stocks [2] - HHLR reduced its positions in Alibaba and BeiGene, while Alibaba's stock price increased by 56% and BeiGene's by 47% during the first quarter [2] Group 3 - Berkshire Hathaway, led by Warren Buffett, significantly reduced its bank stock holdings while maintaining its position in Apple, valued at $66.6 billion [3] - Berkshire increased its stake in Constellation Brands by over 113% and doubled its holdings in Pool Corp [3] - Buffett indicated a lack of attractive investment opportunities currently, with cash reserves reaching $347.7 billion [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年5月9日， 董事會薪酬委員會根據2016期權及激勵計劃的條款向一百九十二名承授人授出涉 及合共42,009股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 於2025年5月9日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予一百九 十二名承授人合共42,009股美國存託股份受限制股份單位。該等受限制股份單位 相當於546,117股股份，約佔本公告之日公司發行股份總數的0.04%。 授出受限制股份單位詳情 1 授出日期： 2025年5月9日 承授人數目： 一百九十二名 已授出受限制股份單位 涉及的相關股份數目： 546,117 受限制股份單位總數 （美國存託股份）: ...

Group 1 - HHLR Advisors reported a total market value increase from $2.887 billion to $3.539 billion, a nearly 23% rise in Q1 2025 [1] - HHLR's top ten holdings include Pinduoduo, Alibaba, Futu Holdings, BeiGene, NetEase, Beike, Legend Biotech, JD.com, Vipshop, and WNS Holdings, with 9 out of 10 being Chinese concept stocks [1][2] - HHLR made new investments in 10 companies including Atour Group, Huazhu Group, Baidu, and Li Auto, with significant increases in holdings for Yum China, Li Auto, and Baidu [2] Group 2 - Jinglin Asset Management's Hong Kong subsidiary reported a total market value of $3.228 billion, showing an increase from the previous year [3] - Jinglin's new investments include Alibaba and Hesai Technology, while it increased holdings in Meta, Beike, TSMC, and New Oriental, and reduced positions in Google, Microsoft, and Nvidia [3] - The market value increase for both HHLR and Jinglin is attributed to the revaluation of Chinese concept stocks, with the Nasdaq Golden Dragon China Index rising by 13.33% in Q1 2025 [4] Group 3 - The rapid development of AI models like DeepSeek is reshaping the valuation of Chinese tech companies, moving away from traditional pricing models that undervalued growth potential [5] - The shift in valuation logic is driven by the transition of Chinese AI companies from relying on foreign platforms to establishing their own technological capabilities [5]

Core Viewpoint - The article discusses the recent quarterly holdings of major investment firms, highlighting significant investments in Chinese stocks and the impact of the revaluation of Chinese tech stocks on their portfolios [2][8]. Group 1: HHLR Advisors Holdings - HHLR Advisors reported a total holding value increase from $2.887 billion to $3.539 billion, a nearly 23% rise in Q1 2025 [2]. - The top ten holdings of HHLR include Pinduoduo, Alibaba, Futu Holdings, BeiGene, NetEase, Beike, Legend Biotech, JD.com, Vipshop, and WNS Holdings, with nine of these being Chinese stocks [2]. - HHLR made new investments in ten companies, including Atour Group, Huazhu Group, Baidu, Yuchai International, and Li Auto, with significant increases in holdings for Yum China, Li Auto, and Baidu [4]. Group 2: Performance of New Investments - New investments by HHLR in Yuchai International saw an 80% increase, while BOSS Zhipin and Li Auto rose by 34% and 20%, respectively, as of May 14 [4]. - HHLR increased its holdings in eight companies, including Futu Holdings and Pinduoduo, with Futu Holdings experiencing a 40% rise and Pinduoduo a 23% rise [4]. - HHLR reduced its positions in Alibaba and BeiGene, with Alibaba's stock rising by 56% and BeiGene by 47% during the same period [4]. Group 3: Jinglin Asset Management Holdings - Jinglin Asset Management reported a total holding value of $3.228 billion as of Q1 2025, showing an increase from the previous year [6]. - New investments included Alibaba and Hesai Technology, while they increased holdings in Meta, Beike, TSMC, and New Oriental, and reduced positions in Google, Microsoft, and others [6]. - The top ten holdings of Jinglin include Meta, Pinduoduo, NetEase, and others, with a total holding value of $2.784 billion, representing 86.24% of their total U.S. stock holdings [6]. Group 4: Market Trends and Revaluation - The increase in holdings for HHLR and Jinglin is attributed to the revaluation of Chinese tech stocks, with the Nasdaq Golden Dragon China Index rising by 13.33% in Q1 2025 [8]. - The rapid development of AI models like DeepSeek is reshaping market perceptions of Chinese tech companies, moving away from traditional valuation methods [8]. - The shift in valuation logic is driven by the emergence of independent technological capabilities in Chinese AI firms, leading to a reassessment of their long-term growth potential [9].

Core Viewpoint - BeiGene reported a significant revenue increase in Q1 2025, achieving 8.048 billion yuan, a year-on-year growth of 50.2%, with a notable reduction in net loss, indicating a positive trend in financial performance [1][2] Financial Performance - Q1 2025 revenue reached 8.048 billion yuan, up 50.2% year-on-year, with product revenue at 7.985 billion yuan, a 49.9% increase [1] - The net profit attributable to shareholders was -95 million yuan, a substantial improvement from -1.908 billion yuan in the same period last year [1] - According to GAAP, the company achieved its first quarterly profit, aligning with market expectations [1] Product Sales Growth - The growth in product revenue was primarily driven by self-developed product Zanubrutinib, along with sales increases of Tislelizumab and Amgen licensed products [1] - Zanubrutinib's global sales totaled 5.692 billion yuan, reflecting a 63.7% increase, with U.S. sales at 4.041 billion yuan, up 61.9% [1] - European sales of Zanubrutinib reached 836 million yuan, a 75.4% increase, while sales in China were 590 million yuan, up 43.1% [1] Future Outlook - Sales of Tislelizumab in Q1 2025 amounted to 1.245 billion yuan, marking a 19.3% increase [2] - The company maintains its full-year revenue guidance for 2025 at 4.9 to 5.3 billion USD, driven by the strong market position of Zanubrutinib in the U.S. and ongoing expansion in Europe and other key global markets [2]